Can you explain the NIAGARA trial evaluating neoadjuvant durvalumab (programmed death‑ligand 1 inhibitor) plus gemcitabine‑cisplatin versus gemcitabine‑cisplatin alone in cisplatin‑eligible patients with muscle‑invasive bladder cancer (clinical stage T2‑T4a, N0‑1, M0) undergoing radical cystectomy?

NIAGARA Trial Overview

The NIAGARA trial demonstrated that adding perioperative durvalumab (a PD-L1 inhibitor) to standard neoadjuvant gemcitabine-cisplatin chemotherapy significantly improves both event-free survival and overall survival in cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC), and this regimen has now received FDA approval. 1, 2, 3, 4

Trial Design and Patient Population

The NIAGARA trial (NCT03732677) was a randomized, open-label, phase 3 study that enrolled 1,063 cisplatin-eligible patients with previously untreated MIBC (clinical stage T2-T4a, N0-1, M0) who were candidates for radical cystectomy 3, 4. Patients were randomized 1:1 to:

• Intervention arm (n=533): Neoadjuvant durvalumab 1,500 mg + gemcitabine-cisplatin every 3 weeks for 4 cycles → radical cystectomy → adjuvant durvalumab 1,500 mg every 4 weeks for 8 cycles
• Control arm (n=530): Neoadjuvant gemcitabine-cisplatin every 3 weeks for 4 cycles → radical cystectomy alone (no adjuvant therapy)

The trial excluded patients with prior systemic chemotherapy or immunotherapy, active autoimmune disease, or those requiring immunosuppressive medications 2.

Primary and Secondary Outcomes

Event-Free Survival (Primary Endpoint)

At median follow-up of 42.3 months, the durvalumab arm showed superior event-free survival 1, 3:

• 24-month EFS: 67.8% (durvalumab) vs. 59.8% (control)
• Hazard ratio: 0.68 (95% CI: 0.56-0.82; p<0.001)
• Median EFS was not reached in the durvalumab arm vs. 46.1 months in the control arm 4

Overall Survival (Key Secondary Endpoint)

The trial demonstrated statistically significant OS benefit 1, 3, 4:

• 24-month OS: 82.2% (durvalumab) vs. 75.2% (control)
• Hazard ratio: 0.75 (95% CI: 0.59-0.93; p=0.01)
• Median OS was not reached in either arm at the time of analysis

Pathologic Complete Response

While pCR was a dual primary endpoint, there was no statistically significant difference between arms 4. However, the survival benefits were achieved regardless of pCR status.

Safety Profile

The addition of durvalumab did not substantially increase toxicity 3, 4:

• Grade 3-4 treatment-related adverse events: 40.6% (durvalumab) vs. 40.9% (control)
• Treatment-related deaths: 0.6% in each arm
• Radical cystectomy completion rate: 88.0% (durvalumab) vs. 83.2% (control)

The safety profile was consistent with prior durvalumab trials in combination with platinum-based chemotherapy 4.

Clinical Implementation

The 2025 European Association of Urology guidelines now reference the NIAGARA trial results, noting that approval for this perioperative durvalumab regimen is pending 1. The FDA approved durvalumab for this indication on March 28,2025 2, 4.

Key Clinical Considerations:

• This regimen applies specifically to cisplatin-eligible patients with MIBC
• The trial design does not allow isolation of whether benefit derives primarily from neoadjuvant or adjuvant durvalumab—both phases are integral to the regimen 2
• Patients must be able to tolerate both chemotherapy and immunotherapy without contraindications to either
• The regimen requires commitment to both pre- and post-surgical immunotherapy phases

Important Caveats:

• Patients with EGFR mutations or ALK rearrangements were excluded from efficacy analyses 2
• Active autoimmune disease or requirement for immunosuppression within 14 days of treatment initiation are contraindications 2
• Renal function must support cisplatin eligibility (typically creatinine clearance ≥60 mL/min)

Cost-Effectiveness

A German healthcare system analysis found the NIAGARA regimen cost-effective at willingness-to-pay thresholds of €100,000 per QALY gained, with 76.5% probability of cost-effectiveness 5. The incremental cost of €13,162 was offset by reduced need for expensive subsequent therapies in the metastatic setting.

Context Within Treatment Landscape

The NIAGARA trial represents a paradigm shift for cisplatin-eligible MIBC patients, building upon the established benefit of neoadjuvant cisplatin-based chemotherapy 6. For cisplatin-ineligible patients, alternative strategies including enfortumab vedotin plus pembrolizumab and intravesical TAR-200 with systemic immunotherapy are under investigation 7.